GlassScriptPhysician profile
Prudence Ashie Mancho
NPI 1891063822
$760.58
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.04 · 2023: $213 · 2024: $265 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $147.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $146.00 | 2023-2025 | Airsupra, Xigduo, Breztri |
| Amgen INC. | $124.94 | 2024-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $67.42 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Exact Sciences Corporation | $47.11 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $41.04 | 2021 | |
| Seqirus USA INC | $39.86 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Biogen, INC. | $25.47 | 2025 | Spinraza |
| Novavax INC | $23.53 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.22 | 2023 | |
| Hologic Sales and Service, LLC | $21.63 | 2025 | Aptima |
| Sanofi Pasteur INC. | $21.15 | 2023 | |
| Boston Scientific Corporation | $17.52 | 2025 | Bodyguardian |
| Nevro Corp. | $14.05 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prudence Mancho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.